|Bid||5.0120 x 0|
|Ask||5.1160 x 0|
|Day's Range||4.8765 - 4.8765|
|52 Week Range||2.5320 - 9.4000|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2023 - Mar 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for 1S9.BE
CAMBRIDGE, Mass., January 13, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 13,500 shares of its common stock to five new employees, consisting of stock options to purchase an aggregate of 9,000 shares of common stock and restricted stock units ("RSUs"), coverin
CAMBRIDGE, Mass., January 05, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the appointment of Claire M. Fraser, Ph.D., to its Board of Directors. Dr. Fraser will begin serving on Seres’ Board, effective immediately.
CAMBRIDGE, Mass., January 04, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 a.m. PST / 11:15 a.m. EST.